Literature DB >> 23396924

Psoriasis aggravation due to lapatinib.

Meltem Selam1.   

Abstract

Our patient was a 35-year-old woman, who had undergone right radically modified mastectomy and axillary-lymph-nodes dissection in June 2004. The stage of the patient was T2N0M0. She was treated with six cycles of FAC (5-fluorouracil, doxorubicin, cyclofosfamid), tamoxifen after chemotherapy. In June 2008, right axillary lymphadenopathy progressed and was treated with docetaxel and capecitabine after a hand-foot reaction was observed in the patient as an adverse reaction to capacitabine; the treatment was continued with only trastuzmab between February 2009 and April 2010. The addition of vinoralbine was needed due to the newly developed right paratracheal lymphadenopthy in April 2010. After six cycles of chemotherapy we achieved stable disease; she received only trastuzumab; later on, in control thorax CT, multiple metastatic models were observed in April 2011 and thus lapatinip plus capecitabine treatment was started. After one cycle of chemotherapy her psoriatic lesions were aggravated and we had to stop the treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396924      PMCID: PMC3604298          DOI: 10.1136/bcr-2012-007592

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  The prevalence of psoriasis in the world.

Authors:  S P Raychaudhuri; E M Farber
Journal:  J Eur Acad Dermatol Venereol       Date:  2001-01       Impact factor: 6.166

Review 2.  The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis.

Authors:  Meghan O'Brien; John Koo
Journal:  J Drugs Dermatol       Date:  2006-05       Impact factor: 2.114

3.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

Review 4.  Drug-induced psoriasis. Recognition and management.

Authors:  N Tsankov; I Angelova; J Kazandjieva
Journal:  Am J Clin Dermatol       Date:  2000 May-Jun       Impact factor: 7.403

5.  Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

Authors:  K L Blackwell; M D Pegram; E Tan-Chiu; L S Schwartzberg; M C Arbushites; J D Maltzman; J K Forster; S D Rubin; S H Stein; H J Burstein
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

6.  Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

Authors:  Henry L Gomez; Dinesh C Doval; Miguel A Chavez; Peter C-S Ang; Zeba Aziz; Shona Nag; Christina Ng; Sandra X Franco; Louis W C Chow; Michael C Arbushites; Michelle A Casey; Mark S Berger; Steven H Stein; George W Sledge
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

7.  A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

Authors:  H J Burstein; A M Storniolo; S Franco; J Forster; S Stein; S Rubin; V M Salazar; K L Blackwell
Journal:  Ann Oncol       Date:  2008-02-17       Impact factor: 32.976

Review 8.  Epidemiology of psoriasis.

Authors:  Luigi Naldi
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2004-06

9.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Authors:  David Cameron; Michelle Casey; Michael Press; Deborah Lindquist; Tadeusz Pienkowski; C Gilles Romieu; Stephen Chan; Agnieszka Jagiello-Gruszfeld; Bella Kaufman; John Crown; Arlene Chan; Mario Campone; Patrice Viens; Neville Davidson; Vera Gorbounova; Johannes Isaac Raats; Dimosthenis Skarlos; Beth Newstat; Debasish Roychowdhury; Paolo Paoletti; Cristina Oliva; Stephen Rubin; Steven Stein; Charles E Geyer
Journal:  Breast Cancer Res Treat       Date:  2008-01-11       Impact factor: 4.872

10.  HER2 breast cancer therapies: a review.

Authors:  Conleth G Murphy; Shanu Modi
Journal:  Biologics       Date:  2009-07-13
View more
  1 in total

1.  Synergistic induction of IL-23 by TNFα, IL-17A, and EGF in keratinocytes.

Authors:  Benjamin Ehst; Zhiping Wang; Justin Leitenberger; Danielle McClanahan; Rachel De La Torre; Erika Sawka; Alex G Ortega-Loayza; Jennifer Strunck; Teri Greiling; Eric Simpson; Yuangang Liu
Journal:  Cytokine       Date:  2020-11-02       Impact factor: 3.861

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.